Kymera Therapeutics (KYMR) News Today $48.39 -0.21 (-0.43%) Closing price 04:00 PM EasternExtended Trading$49.50 +1.11 (+2.29%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Stifel Nicolaus Keeps Their Buy Rating on Kymera Therapeutics (KYMR)June 8 at 4:52 PM | theglobeandmail.comStocks Showing Market Leadership: Kymera Therapeutics Earns 92 RS RatingJune 6, 2025 | msn.comB. Riley Reduces Earnings Estimates for Kymera TherapeuticsKymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Equities research analysts at B. Riley reduced their Q3 2025 earnings per share (EPS) estimates for shares of Kymera Therapeutics in a report issued on Tuesday, June 3rd. B. Riley analyst K. Patel now anticipates that the company will post eJune 6, 2025 | marketbeat.comAmeriprise Financial Inc. Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Ameriprise Financial Inc. acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 8,544 shares of the company's stock, valued atJune 6, 2025 | marketbeat.comQ2 EPS Forecast for Kymera Therapeutics Boosted by AnalystJune 6, 2025 | americanbankingnews.comKymera Therapeutics (NASDAQ:KYMR) Trading 6.3% Higher - Here's What HappenedKymera Therapeutics (NASDAQ:KYMR) Trading 6.3% Higher - What's Next?June 5, 2025 | marketbeat.comLeerink Partnrs Has Bullish Forecast for KYMR Q2 EarningsKymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Stock analysts at Leerink Partnrs raised their Q2 2025 earnings estimates for shares of Kymera Therapeutics in a research note issued on Monday, June 2nd. Leerink Partnrs analyst F. Khurshid now expects that the company will earn ($1.08) perJune 5, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Upgraded to Buy at B. RileyJune 5, 2025 | americanbankingnews.comJPMorgan Chase & Co. Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $64.00June 5, 2025 | americanbankingnews.comKymera Therapeutics (NASDAQ:KYMR) Sees Strong Trading Volume on Analyst UpgradeJune 5, 2025 | americanbankingnews.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Sells $311,101.00 in StockKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Jeffrey W. Albers sold 6,349 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $311,101.00. The sale was disclosed in a filing with the SEC, which is available through this link.June 4, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Sells $553,200.00 in StockKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Elena Ridloff sold 12,000 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $46.10, for a total value of $553,200.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.June 4, 2025 | marketbeat.comInsider Selling: Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Sells 30,000 Shares of StockKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the sale, the chief executive officer now directly owns 660,482 shares of the company's stock, valued at approximately $32,363,618. This represents a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.June 4, 2025 | marketbeat.comBiotech and Social Media Stocks Defy Market Stagnation as Analysts Turn PositiveJune 4, 2025 | investing.comMorgan Stanley Upgrades Kymera Therapeutics (KYMR)June 4, 2025 | msn.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Jeffrey W. Albers Sells 6,349 SharesJune 4, 2025 | insidertrades.comKymera Therapeutics (NASDAQ:KYMR) Raised to "Overweight" at Morgan StanleyJune 4, 2025 | americanbankingnews.comBank of America Upgrades Kymera Therapeutics (NASDAQ:KYMR) to "Buy"June 4, 2025 | americanbankingnews.comKymera Therapeutics, Inc.’s (KYMR) Upgraded to Buy Following Positive Phase 1 Results for Oral STAT6 DegraderJune 4, 2025 | insidermonkey.comKymera Therapeutics (NASDAQ:KYMR) Upgraded by Bank of America to "Buy" RatingBank of America upgraded Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 target price on the stock in a research note on Monday.June 3, 2025 | marketbeat.comWhat 6 Analyst Ratings Have To Say About Kymera TherapeuticsJune 3, 2025 | benzinga.comBofA Upgrades Kymera Therapeutics (KYMR) to Buy, Lifts PT to $51June 3, 2025 | msn.comKymera draws upgrades after early-stage data for anti-inflammatory agentJune 3, 2025 | msn.comKymera Therapeutics (NASDAQ:KYMR) Shares Gap Up - Time to Buy?Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up - Here's What HappenedJune 3, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Sees Large Volume Increase Following Analyst UpgradeKymera Therapeutics (NASDAQ:KYMR) Sees Strong Trading Volume on Analyst UpgradeJune 3, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $64.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. lifted their price target on shares of Kymera Therapeutics from $57.00 to $64.00 and gave the stock an "overweight" rating in a report on Tuesday.June 3, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Upgraded by B. Riley to Buy RatingB. Riley upgraded shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $60.00 price target for the company in a research note on Tuesday.June 3, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Upgraded by Morgan Stanley to "Overweight" RatingMorgan Stanley upgraded shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and set a $79.00 target price for the company in a research report on Tuesday.June 3, 2025 | marketbeat.comWhy Kymera Therapeutics, Inc. (KYMR) Skyrocketed On MondayJune 3, 2025 | msn.comKymera Therapeutics Shares Surge 37% on Promising KT-621 Trial ResultsJune 2, 2025 | msn.comKymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment DataJune 2, 2025 | seekingalpha.comKymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 DegraderJune 2, 2025 | globenewswire.comUniversal Beteiligungs und Servicegesellschaft mbH Invests $4.61 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 114,587 shareJune 2, 2025 | marketbeat.comBank of America Corp DE Trims Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Bank of America Corp DE decreased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 43.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,260 shares of the company's stock aftJune 2, 2025 | marketbeat.comKymera Therapeutics to Announce Phase 1 Trial Results for KT-621 in Healthy Volunteers on June 2, 2025June 1, 2025 | nasdaq.comKymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025May 31, 2025 | insidermonkey.comKymera jumps 16% as it prepares to release phase 1 data on inflammatory diseases assetMay 30, 2025 | msn.comKymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025May 30, 2025 | globenewswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 5.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The instituMay 30, 2025 | marketbeat.comMillennium Management LLC Raises Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Millennium Management LLC lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 205.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 115,918 shareMay 30, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Trading Down 4.3% - Time to Sell?Kymera Therapeutics (NASDAQ:KYMR) Trading Down 4.3% - Here's What HappenedMay 29, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Stock Price Up 4.8% - What's Next?Kymera Therapeutics (NASDAQ:KYMR) Trading Up 4.8% - Here's WhyMay 29, 2025 | marketbeat.comKymera Therapeutics to Participate in Upcoming June Investor ConferencesMay 29, 2025 | globenewswire.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seventeen ratings firms that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating, twelve have assigned a buyMay 29, 2025 | marketbeat.comVoloridge Investment Management LLC Sells 87,533 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Voloridge Investment Management LLC decreased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 37.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 147,238 shares of the company's stock afteMay 27, 2025 | marketbeat.comTwo Sigma Investments LP Has $6.99 Million Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Two Sigma Investments LP cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 35.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 173,753 shares of the company's stock after selling 96,282 shaMay 27, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires Shares of 9,838 Kymera Therapeutics, Inc. (NASDAQ:KYMR)BNP Paribas Financial Markets bought a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,838 shares of the company's stock, vMay 27, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 76,000 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Two Sigma Advisers LP trimmed its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 22.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 260,300 shares of the company's stock afterMay 25, 2025 | marketbeat.comDeutsche Bank AG Has $2.91 Million Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Deutsche Bank AG raised its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 65.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,442 shares of the company's stock after buying an additional 28,72May 24, 2025 | marketbeat.comWoodline Partners LP Has $21.62 Million Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Woodline Partners LP boosted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 2.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 537,428 shares of the company's stock after acquiringMay 23, 2025 | marketbeat.com Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address KYMR Media Mentions By Week KYMR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYMR News Sentiment▼0.641.01▲Average Medical News Sentiment KYMR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYMR Articles This Week▼206▲KYMR Articles Average Week Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRNA News Today ASND News Today VTRS News Today QGEN News Today BPMC News Today ROIV News Today RVMD News Today BBIO News Today ELAN News Today VRNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYMR) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
